| Literature DB >> 11800588 |
Abstract
The TB community now envisions a turning point in the development of improved TB vaccines for both high and low incidence countries. With a number of viable TB vaccine candidates now available for testing, the investigation of safety and immunogenicity in human clinical trials is seen as the driving force for the future development of effective vaccines for the prevention of tuberculosis. Copyright 2001 Harcourt Publishers Ltd.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11800588 DOI： 10.1054/tube.2001.0308
Source DB: PubMed Journal: Tuberculosis (Edinb) ISSN： 1472-9792 Impact factor: 3.131